BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency

 
• By Derrick Gingery

New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.

Team efficiency
Quicker, targeted advice on from the FDA is expected to help speed biosimilar development. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics